Product Name: AZD-5363
 CAT#: A-1183

Request AZD-5363
 Synonym:AZD-5363

AZD-5363 Chemical Structure
AZD-5363 chemical structure


5 stars, based on 836 reviews

IUPAC/Chemical name:

Price of AZD-5363

We offer a substantial discount on larger orders,
please inquire via sales@activebiochem.com
or Fax: 1-201-884-1288 (USA Fax#)


Biological Activity
AZD-5363 is an orally active selective inhibitor of PKB/Akt, a key enzyme in the PI3K/PKB/mTOR tumour cell survival pathway, and dysregulation of this pathway leads to tumour resistance to a number of important anti-cancer drugs.
Technical Data

Mol. Formula: C21H25ClN6O2
MW: 428.91
CAS#: 1143532-39-1
Purity: >99%
AZD-5363 MSDS AZD-5363 CoA

Reference


AZD5363 is a novel pyrrolopyrimidine derived compound which inhibited all AKT isoforms with a potency of <10 nM, and inhibited phosphorylation of AKT substrates in cells with a potency of ~0.3 to 0.8 µM. AZD5363 monotherapy inhibited the proliferation of 41/182 solid and hematologic tumor cell lines with a potency of <3 µM. Cell lines derived from breast cancers showed the highest frequency of sensitivity. There was a significant relationship between the presence of PIK3CA and/or PTEN mutations and sensitivity to AZD5363, and between RAS mutations and resistance. Oral dosing of AZD5363 to nude mice caused dose- and time-dependent reduction of PRAS40, GSK3β and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 ~0.1 µM total plasma exposure), reversible increases in blood glucose concentrations and dose-dependent decreases in fluorodeoxyglucose (FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 caused dose-dependent inhibition of the growth of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhanced the antitumor activity of docetaxel, lapatinib and trastuzumab in breast cancer xenografts. It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN and RAS. AZD5363 is currently in phase I clinical trials. (source: Mol Cancer Ther molcanther.0824.2011)




Purchase(buy) inhibitor AZD-5363 at Active Biochem and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.